These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

104 related items for PubMed ID: 5520073

  • 1. [Effect of chlodithane (o,p'-DDD) on transcortin binding ability in Itsenko-Cushing's disease].
    Tron'ko MD.
    Fiziol Zh; 1970; 16(6):844-5. PubMed ID: 5520073
    [No Abstract] [Full Text] [Related]

  • 2. Remission in Cushing's syndrome with o,p'-DDD.
    Southren AL, Tochimoto S, Strom L, Ratuschni A, Ross H, Gordon G.
    J Clin Endocrinol Metab; 1966 Mar; 26(3):268-78. PubMed ID: 4286017
    [No Abstract] [Full Text] [Related]

  • 3. [Effect of o,p'-DDD on the binding ability of transcortin in dogs, rats, guinea pigs and chickens].
    Tron'ko MD, Kravchenko VI.
    Fiziol Zh; 1971 Mar; 17(2):245-7. PubMed ID: 5565999
    [No Abstract] [Full Text] [Related]

  • 4. [Effect of the adrenal cortex blockader O,P'-dichlorodiphenyldichloroethane (O,P'-DDD) on the acetylation processes in the liver].
    Shevchenko AV, Kosbel' NN.
    Vrach Delo; 1974 Jan; (1):72-4. PubMed ID: 4468586
    [No Abstract] [Full Text] [Related]

  • 5. [Effect of o,p'-DDD on transcortin-binding ability in dogs].
    Komissarenko VP, Mikosha AS, Tron'ko ND.
    Fiziol Zh; 1970 Jan; 16(1):10-3. PubMed ID: 5488760
    [No Abstract] [Full Text] [Related]

  • 6. [Treatment of Cushing's syndrome and adrenal cancer with O,p-DDD].
    Kinouchi T, Shimizu N, Ibayashi H, Demura H, Oshima H.
    Horumon To Rinsho; 1982 Aug; 30(8):841-51. PubMed ID: 7139984
    [No Abstract] [Full Text] [Related]

  • 7. Effect of o,p'-DDD on cortisol secretory pattern in Cushing's syndrome.
    Hellman L, Weitzman ED, Roffwarg H, Fukushima DK, Yoshida K, Zumoff B, Gallagher TF.
    J Clin Endocrinol Metab; 1970 Aug; 31(2):227-30. PubMed ID: 4316529
    [No Abstract] [Full Text] [Related]

  • 8. [Hydrocortisone-transcortin binding in Itsenko-Cushing disease and adrenal cortex tumors].
    Ramikh MV, Rozen VB, Kertsman VI, Marova EI.
    Probl Endokrinol (Mosk); 1969 Aug; 15(4):35-40. PubMed ID: 5368709
    [No Abstract] [Full Text] [Related]

  • 9. [Control of adrenal adenocarcinoma and Cushing's syndrome with ketoconazole].
    Garciá-Girón C, Artal A, Garrido P, González Barón M.
    Med Clin (Barc); 1989 Jan 14; 92(1):36-7. PubMed ID: 2716379
    [No Abstract] [Full Text] [Related]

  • 10. Amino-glutethimide and metastatic adrenal cancer. Maintained reversal (six months) of Cushing's syndrome.
    Schteingart DE, Cash R, Conn JW.
    JAMA; 1966 Nov 28; 198(9):1007-10. PubMed ID: 5953457
    [No Abstract] [Full Text] [Related]

  • 11. [Treatment with o,p'-DDD of inoperable forms of malignant adrenal gland neoplasms].
    Perevodchikova NI, Platinskiĭ LV, Kertsman VI.
    Vopr Onkol; 1972 Nov 28; 18(11):24-9. PubMed ID: 4645074
    [No Abstract] [Full Text] [Related]

  • 12. [Hormonally acitve cancer of the adrenal cortex treated with o, p'-DDD].
    Hartwig W, Massalski W, Kasperlik-Zaluska A, Migdalska B, Szamatowicz M, Jakowicki J.
    Endokrynol Pol; 1968 Nov 28; 19(2):187-200. PubMed ID: 5668901
    [No Abstract] [Full Text] [Related]

  • 13. ADRENOCORTICAL CARCINOMA TREATED WITH O,P' -DDD.
    MONTGOMERY DA, WELBOURN RB.
    Br Med J; 1965 May 22; 1(5446):1356-8. PubMed ID: 14280300
    [No Abstract] [Full Text] [Related]

  • 14. [Various etiologies and therapeutic possibilities in Cushing's syndrome. 2].
    Staub JJ, Luton JP, Philbert M, Bricaire H.
    Praxis; 1968 Oct 29; 57(43):1493-8. PubMed ID: 5756517
    [No Abstract] [Full Text] [Related]

  • 15. Effects of o,p'-DDD on cortisol and 6-beta-hydroxycortisol secretion and metabolism in man.
    Fukushima DK, Bradlow HL, Hellman L.
    J Clin Endocrinol Metab; 1971 Feb 29; 32(2):192-200. PubMed ID: 4321502
    [No Abstract] [Full Text] [Related]

  • 16. The protracted effect of o,p'-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.
    Leiba S, Weinstein R, Shindel B, Lapidot M, Stern E, Levavi H, Rusecki Y, Abramovici A.
    Ann Endocrinol (Paris); 1989 Feb 29; 50(1):49-53. PubMed ID: 2729882
    [Abstract] [Full Text] [Related]

  • 17. o,p'-DDD (mitotane) treatment for Cushing's syndrome: adrenal drug concentration and inhibition in vitro of steroid synthesis.
    Touitou Y, Moolenaar AJ, Bogdan A, Auzéby A, Luton JP.
    Eur J Clin Pharmacol; 1985 Feb 29; 29(4):483-7. PubMed ID: 4092727
    [Abstract] [Full Text] [Related]

  • 18. Personality characteristics and quality of life in patients treated for Cushing's syndrome.
    Sonino N, Bonnini S, Fallo F, Boscaro M, Fava GA.
    Clin Endocrinol (Oxf); 2006 Mar 29; 64(3):314-8. PubMed ID: 16487442
    [Abstract] [Full Text] [Related]

  • 19. [Our experience with o,p'-DDD in the treatment of hypercorticism].
    Mathieu De Fossey B, Luton JP, Bricaire H.
    Ann Endocrinol (Paris); 1968 Mar 29; 29(1):93-102. PubMed ID: 4872638
    [No Abstract] [Full Text] [Related]

  • 20. [Treatment of Cushing's disease with o, p'-DDD (author's transl)].
    Nakagawa K, Ito S, Ohara T, Kubo M, Horikawa H.
    Horumon To Rinsho; 1981 Sep 29; 29(9):1135-9. PubMed ID: 7326856
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.